Expertise in
66
conditions

Dr. Richard T. Lee

Hematology Oncology | Hematology | Oncology
Tennessee Cancer Specialists PLLC
1415 Old Weisgarber Rd, Suite 200, 
Knoxville, TN 
Accepting New Patients
Offers Telehealth
Expertise in
66
conditions
Tennessee Cancer Specialists PLLC
1415 Old Weisgarber Rd, Suite 200, 
Knoxville, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Richard Lee is a Hematologist Oncology specialist and a Hematologist in Knoxville, Tennessee. Dr. Lee is highly rated in 66 conditions, according to our data. His top areas of expertise are Childhood Iron Deficiency Anemia, Paget Disease of the Breast, Angiosarcoma, and Lung Cancer. Dr. Lee is currently accepting new patients.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in KY
Hospital Affiliations
Fort Sanders Regional Medical Center
Middlesboro Arh Hospital
Physicians Regional Medical Center
Claiborne Medical Center
Lafollette Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

TENNESSEE CANCER SPECIALISTS PLLC
1415 Old Weisgarber Rd, Suite 200, Knoxville, TN 37909
Other Locations
TENNESSEE CANCER SPECIALISTS PLLC
900 E Hill Ave, Suite 230, Knoxville, TN 37915

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer
EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: April 23, 2025
Intervention Type: Drug, Device
Study Phase: Phase 2
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Terminated
Publish Date: December 09, 2024
Intervention Type: Drug
Study Drugs: Tazemetostat, Abiraterone/prednisone, Enzalutamide
Study Phase: Phase 1/Phase 2
Investigator-Initiated, Pilot Translational Study of Circulating Tumor Cells to Identify Predictive Factors of Response to Abiraterone Acetate in Men With Castration-Resistant Prostate Cancer
Investigator-Initiated, Pilot Translational Study of Circulating Tumor Cells to Identify Predictive Factors of Response to Abiraterone Acetate in Men With Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2024
Intervention Type: Drug
Study Phase: Not Applicable
SYMPHONY-II: A Phase II Open-Label, Multicenter Trial of Oral Tazemetostat in Combination With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
SYMPHONY-II: A Phase II Open-Label, Multicenter Trial of Oral Tazemetostat in Combination With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
Enrollment Status: Terminated
Publish Date: March 25, 2024
Intervention Type: Drug, Combination product
Study Drug: Tazemetostat
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination With Nivolumab in Patients With Advanced/Metastatic Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination With Nivolumab in Patients With Advanced/Metastatic Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: March 17, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Feasibility Study of Durvalumab (MEDI4736) Alone or in Combination With Oleclumab (MEDI9447) as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)
A Feasibility Study of Durvalumab (MEDI4736) Alone or in Combination With Oleclumab (MEDI9447) as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)
Enrollment Status: Completed
Publish Date: September 13, 2022
Intervention Type: Drug
Study Drugs: Durvalumab, Oleclumab
Study Phase: Phase 1
A Phase 2, Multicenter, Single-Arm Trial of CV301 in Combination With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
A Phase 2, Multicenter, Single-Arm Trial of CV301 in Combination With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Enrollment Status: Completed
Publish Date: April 27, 2022
Intervention Type: Biological
Study Drugs: CV-301, Atezolizumab
Study Phase: Phase 2
A Phase 1b/2 Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor CB-839 in Combination With the PARP Inhibitor Talazoparib in Patients With Advanced or Metastatic Solid Tumors
A Phase 1b/2 Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor CB-839 in Combination With the PARP Inhibitor Talazoparib in Patients With Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: February 17, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
Enrollment Status: Completed
Publish Date: October 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

3 Total Publications

Rosai-Dorfman Disease: Self-Resolving Unilateral Lymphadenopathy and a Brief Review of Literature.
Rosai-Dorfman Disease: Self-Resolving Unilateral Lymphadenopathy and a Brief Review of Literature.
Journal: Case reports in oncological medicine
Published: May 16, 2018
Similar Doctors
Expertise in
110
conditions
Dr. Daniel M. Ibach
Hematology Oncology | Hematology | Oncology
Expertise in
110
conditions
Dr. Daniel M. Ibach
Hematology Oncology | Hematology | Oncology

Tennessee Cancer Specialists PLLC

900 E Hill Ave, Suite 230, 
Knoxville, TN 
 (6.6 mi)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Ibach is a Hematologist Oncology specialist and a Hematologist in Knoxville, Tennessee. Dr. Ibach is highly rated in 110 conditions, according to our data. His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Paget Disease of the Breast, Iron Deficiency Anemia, Breast Cancer, and Bone Marrow Aspiration. Dr. Ibach is currently accepting new patients.

Expertise in
52
conditions
Dr. Thomas B. Repine
Hematology Oncology | Hematology | Oncology
Expertise in
52
conditions
Dr. Thomas B. Repine
Hematology Oncology | Hematology | Oncology

Thompson Oncology Group

1915 White Ave, 
Knoxville, TN 
 (4.8 mi)
865-541-1720
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Thomas Repine is a Hematologist Oncology specialist and a Hematologist in Knoxville, Tennessee. Dr. Repine is highly rated in 52 conditions, according to our data. His top areas of expertise are Angiosarcoma, Paget Disease of the Breast, Inflammatory Breast Cancer, and Familial Colorectal Cancer. Dr. Repine is currently accepting new patients.

Expertise in
96
conditions
Dr. Yi I. Feng
Hematology Oncology | Oncology | Hematology
Expertise in
96
conditions
Dr. Yi I. Feng
Hematology Oncology | Oncology | Hematology

Tennessee Cancer Specialists PLLC

7650 Dannaher Dr, Suite 100, 
Powell, TN 
 (7.5 mi)
865-637-9330
Languages Spoken:
English, Mandarin
See accepted insurances
Accepting New Patients
Offers Telehealth

Yi Feng is a Hematologist Oncology specialist and an Oncologist in Powell, Tennessee. Dr. Feng is highly rated in 96 conditions, according to our data. His top areas of expertise are Iron Deficiency Anemia, Colorectal Cancer, Breast Cancer, Pleuropulmonary Blastoma, and Craniectomy. Dr. Feng is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lee's expertise for a condition
ConditionClose
    View All 14 Distinguished Conditions
    View All 52 Advanced Conditions
    View All 138 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile